These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 18437141)

  • 1. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
    Rabbani A; Alexander GC
    Am J Hypertens; 2008 May; 21(5):509-13. PubMed ID: 18437141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 3. Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy.
    Hong SH; Wang J; Tang J
    Am J Hypertens; 2013 Jul; 26(7):879-87. PubMed ID: 23512697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost.
    Fendrick AM; Smith DG; Chernew ME; Shah SN
    Am J Manag Care; 2001 Sep; 7(9):861-7. PubMed ID: 11570020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.
    Xu KT; Moloney M; Phillips S
    Am J Manag Care; 2003 Aug; 9(8):529-36. PubMed ID: 12921230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive drug prescribing in Grampian.
    Ross S; Macleod MJ
    Br J Clin Pharmacol; 2005 Sep; 60(3):300-5. PubMed ID: 16120069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unintended consequences of caps on Medicare drug benefits.
    Hsu J; Price M; Huang J; Brand R; Fung V; Hui R; Fireman B; Newhouse JP; Selby JV
    N Engl J Med; 2006 Jun; 354(22):2349-59. PubMed ID: 16738271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care.
    Federman AD; Halm EA; Siu AL
    Med Care; 2007 Feb; 45(2):109-15. PubMed ID: 17224772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing costs and improving hypertension management.
    Stankus V; Hemmelgarn B; Campbell NR; Chen G; McAlister FA; Tsuyuki RT
    Can J Clin Pharmacol; 2009; 16(1):e151-5. PubMed ID: 19193969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
    Boulet AP; Tessier G
    Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doctor pharmaceutical utilization behaviour changed by the global budget programme strategies on hypertensive outpatient prescription.
    Wei CK; Wang SM; Yeh MK
    J Eval Clin Pract; 2012 Apr; 18(2):262-8. PubMed ID: 21040251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs.
    Shrank WH; Asch SM; Joseph GJ; Young HN; Ettner SL; Kholodenko Y; Glassman P; Kravitz RL
    Ann Pharmacother; 2006 Sep; 40(9):1534-40. PubMed ID: 16912246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.